On RemeGen (688331.SH/09995.HK) announced that the results of the Phase III clinical study of Telitacicept for Sjögren's Syndrome in China have been published in an abstract on the 2025 ACR website.

The authors describe an interesting approach to studying the dynamics and function of membrane proteins in different lipid environments. The important findings have theoretical and practical ...

China: Telitacicept significantly reduced proteinuria in patients with IgA nephropathy, while maintaining an acceptable ...

Researchers have identified two experimental medications that may be able to promote myelin repair in people with MS, a study ...

Creative Biogene, a leader in innovative solutions for life science research, today announced enhancements to its G protein-coupled receptor (GPCR) assay solutions.

In this valuable study, through carefully executed and rigorously controlled experiments, the authors challenged a previously reported role of the Death Receptor 6 (DR6/Tnfrsf21) in Wallerian ...